Journal of Clinical Oncology, Vol 15, 653-659, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS- related Kaposi's sarcoma after failure of standard chemotherapy

DW Northfelt, BJ Dezube, JA Thommes, R Levine, JH Von Roenn, GM Dosik, A Rios, SE Krown, C DuMond and RD Mamelok
SEQUUS Pharmaceuticals, Inc, Menlo Park, CA, USA. dnorthfelt@pol.net

PURPOSE: To determine the efficacy and safety of pegylated-liposomal doxorubicin in patients with AIDS and Kaposi's sarcoma (AIDS-KS) who experienced failure of standard chemotherapy. METHODS: Fifty-three patients with advanced AIDS-KS who experienced disease progression or intolerable toxicities while receiving standard doxorubicin/bleomycin/vincristine (ABV) or bleomycin/vincristine (BV) chemotherapy were identified from a cohort of patients who were then treated with pegylated-liposomal doxorubicin. Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, Inc, Menlo Park, CA) every 3 weeks. RESULTS: Nineteen patients (36%) had a partial response (PR) and one patient had a clinical complete response (CCR). The median duration of response and time (from study entry) to treatment failure were 128 and 134 days, respectively. Of 28 patients who experienced disease progression while receiving combination regimens that contained standard doxorubicin, the PR rate was 32%, which suggests that the pegylated-liposomal encapsulation increases the therapeutic effect of doxorubicin. Patients obtained clinical benefits such as flattening of lesions (48%), improved lesion color (56%), relief of pain (45%), and loss of edema (83%). Forty-nine percent of patients had more than one clinical benefit. The most common adverse effect was leukopenia, which occurred in 40% of patients. Only 15% of patients had nausea and/or vomiting, none of which was severe; 9% experienced alopecia, also generally mild. CONCLUSION: Pegylated- liposomal doxorubicin offers a new alternative for treatment of patients who have experienced failure of standard chemotherapy for AIDS- KS.

This article has been cited by other articles:

				F. Pastorino, D. Di Paolo, F. Piccardi, B. Nico, D. Ribatti, A. Daga, G. Baio, C. E. Neumaier, C. Brignole, M. Loi, et al. Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin Clin. Cancer Res., November 15, 2008; 14(22): 7320 - 7329. [Abstract] [Full Text] [PDF]

				S. Y. Zafar, D. N. Howell, and J. P. Gockerman Malignancy After Solid Organ Transplantation: An Overview Oncologist, July 1, 2008; 13(7): 769 - 778. [Abstract] [Full Text] [PDF]

				X. Wang, L. Yang, Z. Chen, and D. M. Shin Application of Nanotechnology in Cancer Therapy and Imaging CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110. [Abstract] [Full Text] [PDF]

				B. J. Dezube, S. E. Krown, J. Y. Lee, K. S. Bauer, and D. M. Aboulafia Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study J. Clin. Oncol., March 20, 2006; 24(9): 1389 - 1394. [Abstract] [Full Text] [PDF]

				T. M. Allen, D. R. Mumbengegwi, and G. J.R. Charrois Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates Clin. Cancer Res., May 1, 2005; 11(9): 3567 - 3573. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]

				A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving, and F. M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil(R)): possible role in hypersensitivity reactions Ann. Onc., September 1, 2003; 14(9): 1430 - 1437. [Abstract] [Full Text] [PDF]

				G. J. R. Charrois and T. M. Allen Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1058 - 1067. [Abstract] [Full Text] [PDF]

				S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study J. Clin. Oncol., August 1, 2002; 20(15): 3236 - 3241. [Abstract] [Full Text] [PDF]

				A. Hamilton, L. Biganzoli, R. Coleman, L. Mauriac, P. Hennebert, A. Awada, M. Nooij, L. Beex, M. Piccart, I. Van Hoorebeeck, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx(R), Doxil(R)) at a 6-week interval in patients with metastatic breast cancer Ann. Onc., June 1, 2002; 13(6): 910 - 918. [Abstract] [Full Text] [PDF]

				V. E. Kouloulias, C. E. Dardoufas, J. R. Kouvaris, C. S. Gennatas, A. K. Polyzos, H. J. Gogas, P. H. Sandilos, N. K. Uzunoglu, E. G. Malas, and L. J. Vlahos Liposomal Doxorubicin in Conjunction with Reirradiation and Local Hyperthermia Treatment in Recurrent Breast Cancer: A Phase I/II Trial Clin. Cancer Res., February 1, 2002; 8(2): 374 - 382. [Abstract] [Full Text] [PDF]

				R. Banerjee Liposomes: Applications in Medicine J Biomater Appl, July 1, 2001; 16(1): 3 - 21. [Abstract] [PDF]

				S. M. Moghimi, A. C. Hunter, and J. C. Murray Long-Circulating and Target-Specific Nanoparticles: Theory to Practice Pharmacol. Rev., June 1, 2001; 53(2): 283 - 318. [Abstract] [Full Text] [PDF]

				R. F. Little, K. M. Wyvill, J. M. Pluda, L. Welles, V. Marshall, W. D. Figg, F. M. Newcomb, G. Tosato, E. Feigal, S. M. Steinberg, et al. Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., July 1, 2000; 18(13): 2593 - 2602. [Abstract] [Full Text] [PDF]

				G. Nasti, D. Errante, R. Talamini, G. Rizzardini, M. Fasan, G. Landonio, C. Zeroli, G. Chichino, E. Nigra, E. Vaccher, et al. Vinorelbine Is an Effective and Safe Drug for AIDS-Related Kaposi’s Sarcoma: Results of a Phase II Study J. Clin. Oncol., April 7, 2000; 18(7): 1550 - 1557. [Abstract] [Full Text] [PDF]

				E. T. M. Dams, P. Laverman, W. J. G. Oyen, G. Storm, G. L. Scherphof, J. W. M. van der Meer, F. H. M. Corstens, and O. C. Boerman Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1071 - 1079. [Abstract] [Full Text]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]

				T. W. Cheung, S. C. Remick, N. Azarnia, J. A. Proper, J. R. Barrueco, and B. J. Dezube AIDS-related Kaposi's Sarcoma: A Phase II Study of Liposomal Doxorubicin Clin. Cancer Res., November 1, 1999; 5(11): 3432 - 3437. [Abstract] [Full Text] [PDF]

				P. S. Gill, A. Tulpule, B. M. Espina, S. Cabriales, J. Bresnahan, M. Ilaw, S. Louie, N. F. Gustafson, M. A. Brown, C. Orcutt, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., June 1, 1999; 17(6): 1876 - 1876. [Abstract] [Full Text] [PDF]

				S. E. Krown Clinical Overview: Issues in Kaposi's Sarcoma Therapeutics J Natl Cancer Inst Monographs, April 1, 1998; 1998(23): 59 - 63. [Abstract] [Full Text]

				D. T. Scadden and W. W. Howard AIDS-Related Malignancies Oncologist, April 1, 1998; 3(2): 119 - 123. [Abstract] [Full Text]